REPORT ON EXPERIENCES WITH 2 RECOMBINANT FACTOR-VIII CONCENTRATES - KOGENATE(R) (BAYER) AND RECOMBINATE(R) (BAXTER)

Recently two recombinant factor VIII concentrates, Kogenate(R) (Bayer) and Recombinate(R) (Baxter), were licensed. The results obtained in c linical trials of nearly 300 patients over a time period up to 5 years and our own experience from 112 patients, receiving a total of 29 mil lion units, showed a good clinical and laboratory parameter response i n prophylactic substitution, therapy of bleeding episodes and during o perations. Side-effects were rare and predominantly were of mild chara cter. Inhibitor incidence was not increased. Recombinant factor VIII c oncentrates obviously did not affect the patients' immune systems. The results should encourage a stepwise increase in the number of patient s treated with recombinant factor VIII concentrates.